These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 3291453)

  • 1. Roles of vaccinia virus in the development of new vaccines.
    Moss B; Fuerst TR; Flexner C; Hugin A
    Vaccine; 1988 Apr; 6(2):161-3. PubMed ID: 3291453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccinia and other poxvirus expression vectors.
    Moss B
    Curr Opin Biotechnol; 1992 Oct; 3(5):518-22. PubMed ID: 1368937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant live virus vaccines.
    Mackett M
    Immunol Lett; 1987 Dec; 16(3-4):243-8. PubMed ID: 3327813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes.
    Legrand FA; Verardi PH; Jones LA; Chan KS; Peng Y; Yilma TD
    J Virol; 2004 Mar; 78(6):2770-9. PubMed ID: 14990697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector.
    Ramírez JC; Gherardi MM; Rodríguez D; Esteban M
    J Virol; 2000 Aug; 74(16):7651-5. PubMed ID: 10906221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2.
    Flexner C; Moss B; London WT; Murphy BR
    Vaccine; 1990 Feb; 8(1):17-21. PubMed ID: 2316280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells.
    Bennink JR; Yewdell JW; Smith GL; Moller C; Moss B
    Nature; 1984 Oct 11-17; 311(5986):578-9. PubMed ID: 6332992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.
    Ober BT; Brühl P; Schmidt M; Wieser V; Gritschenberger W; Coulibaly S; Savidis-Dacho H; Gerencer M; Falkner FG
    J Virol; 2002 Aug; 76(15):7713-23. PubMed ID: 12097585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The vaccinia virus as a vector for genetically engineered vaccines and the study of viral protein functions].
    Vopr Virusol; 1986; 31(4):509-12. PubMed ID: 3464128
    [No Abstract]   [Full Text] [Related]  

  • 10. Structural analysis of vaccinia virus DIs strain: application as a new replication-deficient viral vector.
    Ishii K; Ueda Y; Matsuo K; Matsuura Y; Kitamura T; Kato K; Izumi Y; Someya K; Ohsu T; Honda M; Miyamura T
    Virology; 2002 Oct; 302(2):433-44. PubMed ID: 12441087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuated Mengo virus: a new vector for live recombinant vaccines.
    Altmeyer R; Girard M; van der Werf S; Mimic V; Seigneur L; Saron MF
    J Virol; 1995 May; 69(5):3193-6. PubMed ID: 7707549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of lentivirus-like particles alone and in combination with live vaccinia-virus-based vaccines.
    Panicali DL; Mazzara G; Sullivan JL; Hesselton R; Shen L; Letvin N; Daniel M; Desrosiers R; Stott EJ
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1449. PubMed ID: 1466979
    [No Abstract]   [Full Text] [Related]  

  • 13. Host range selection of vaccinia recombinants containing insertions of foreign genes into non-coding sequences.
    Smith KA; Stallard V; Roos JM; Hart C; Cormier N; Cohen LK; Roberts BE; Payne LG
    Vaccine; 1993; 11(1):43-53. PubMed ID: 8427036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Modified vaccinia virus ankara (MVA)--development as recombinant vaccine and prospects for use in veterinary medicine].
    Volz A; Fux R; Langenmayer MC; Sutter G
    Berl Munch Tierarztl Wochenschr; 2015; 128(11-12):464-72. PubMed ID: 26697713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of an attenuated TE3L-deficient vaccinia virus Tian Tan strain.
    Wang Y; Kan S; Du S; Qi Y; Wang J; Liu L; Ji H; He D; Wu N; Li C; Chi B; Li X; Jin N
    Antiviral Res; 2012 Dec; 96(3):324-32. PubMed ID: 23084929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC.
    Paoletti E; Taylor J; Meignier B; Meric C; Tartaglia J
    Dev Biol Stand; 1995; 84():159-63. PubMed ID: 7796949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replicating and host-restricted non-replicating vaccinia virus vectors for vaccine development.
    Moss B
    Dev Biol Stand; 1994; 82():55-63. PubMed ID: 7958483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus.
    Sutter G; Moss B
    Dev Biol Stand; 1995; 84():195-200. PubMed ID: 7796954
    [No Abstract]   [Full Text] [Related]  

  • 19. The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation.
    Kalus RM; Kantor JA; Gritz L; Gómez Yafal A; Mazzara GP; Schlom J; Hodge JW
    Vaccine; 1999 Feb; 17(7-8):893-903. PubMed ID: 10067696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccinia virus expression vectors.
    Mackett M; Smith GL
    J Gen Virol; 1986 Oct; 67 ( Pt 10)():2067-82. PubMed ID: 3531399
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.